Imunon Inc logo

Imunon Inc(IMNN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.63
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IMNN

11/13/2026: IMNN (1-star) is currently NOT-A-BUY. Pass it for now.

Imunon Inc is a clinical-stage biotechnology company specializing in DNA-mediated immunotherapies and non-viral delivery platforms for challenging oncology indications. The company's primary value driver is its lead candidate, IMNN-001, which is advancing through Phase 3 clinical evaluation for advanced ovarian cancer backed by encouraging survival signals. Key opportunities lie in potential registrational milestones and research collaborations, while primary risks include clinical trial uncertainty, high cash burn, and the need for ongoing external financing. The stock best suits risk-tolerant growth investors seeking binary clinical catalysts, requiring careful monitoring of trial enrollment, cash runway, and regulatory developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-growth exposure through its late-stage clinical pipeline, though commercial revenue is currently absent.
Momentum investorStrong fit while signal remains positiveShort-term momentum can surge around clinical trial updates and regulatory catalysts, conditional on a positive trend.
Value investorWeak fitTraditional value metrics do not apply given the absence of earnings, cash flow, and commercial product sales.
Dividend investorWeak fitImunon does not pay dividends and reinvests all capital into drug development.
Low-risk investorWeak fitHigh clinical, regulatory, and stock price volatility make this an unsuitable asset for low-risk strategies.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap clinical biotech stocks frequently experience sharp price swings driven by news flow and market sentiment.
Valuation riskHighValuations are speculative and closely tied to binary clinical trial outcomes rather than fundamental earnings multiples.
Competition risk (oncology therapeutics)Medium / highThe company faces intense competition from well-capitalized biotechnology and pharmaceutical companies developing cancer therapies.
Business qualityMediumWhile scientific platforms show promise, the enterprise lacks commercial infrastructure and validated revenue-generating products.
Dividend incomeLow / noneNo dividend distributions are paid or anticipated in the foreseeable future.
Execution riskHighSuccessful execution of pivotal Phase 3 clinical trials and regulatory navigation are critical for survival.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.08M USD
Price to earnings Ratio -
1Y Target Price 15.8
Price to earnings Ratio -
1Y Target Price 15.8
Volume (30-day avg) 184.8K shares
Beta 2.08
52 Weeks Range 0.50 - 4.35
Updated Date 11/15/2026
52 Weeks Range 0.50 - 4.35
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.31

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -73.94%
Avg. Invested days 10
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IMNN receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
IMNN has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, solid earnings growth (+22.2%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
IMNN's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is IMNN's strongest growth driver at +24.9% FY2025 versus FY2024 (solid, 4 stars). By comparison, earnings growth (+22.2%, solid) is also solid, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 5.9% (soft) and 79.3% of outstanding shares are publicly tradable (solid). Insider ownership of 7.89% supports management-shareholder alignment.

Top 5 Institutional Investors

Armistice Capital, LLC 2.58%
Vanguard Capital Management, LLC 0.84%
Riverview Capital Advisers LLC 0.61%
Geode Capital Management, LLC 0.56%
Virtu Financial LLC 0.31%

Unit Economics (Per $1K Revenue)

★★★★★
IMNN generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
IMNN has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Biopharmaceutical Research and DevelopmentClinical-stage biotechnology pipeline development focused on DNA-mediated immunotherapies.The company does not currently sell commercial products and relies entirely on capital raises, grants, and strategic asset agreements to fund operations.

Valuation

Trailing PE -
Forward PE 16.78
Enterprise Value 6.98M
Price to Sales(TTM) 136.97
Enterprise Value 6.98M
Price to Sales(TTM) 136.97
Enterprise Value to Revenue 4
Enterprise Value to EBITDA 0.91
Shares Outstanding 6.49M
Shares Floating 5.15M
Shares Outstanding 6.49M
Shares Floating 5.15M
Percent Insiders 7.89
Percent Institutions 5.94

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.